Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
AbbVie
M.D. Anderson Cancer Center
Gilead Sciences
University of Washington
Mayo Clinic
Institute of Hematology & Blood Diseases Hospital, China
Sunnybrook Health Sciences Centre
BeOne Medicines
BeOne Medicines
University of Ulm
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
University of Ulm
Acerta Pharma BV
French Innovative Leukemia Organisation
Massachusetts General Hospital
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Roswell Park Cancer Institute
City of Hope Medical Center
Fred Hutchinson Cancer Center
Janssen Pharmaceutical K.K.
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
University of Ulm
University College, London
Institute of Hematology & Blood Diseases Hospital, China
Mayo Clinic
University of Nebraska
Weill Medical College of Cornell University
Kosin University Gospel Hospital
Agenus Inc.
Shanghai Changzheng Hospital
University of Nebraska
French Innovative Leukemia Organisation
TG Therapeutics, Inc.
Eastern Cooperative Oncology Group
Abramson Cancer Center at Penn Medicine
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Thomas Jefferson University
Academic and Community Cancer Research United
Mayo Clinic
Dana-Farber Cancer Institute
Hackensack Meridian Health
University College, London
University of Athens